Latest News
Search News
From MSc Cancer student to Principal Investigator – how do you build a research career?
26th February 2025
When Dr Alex Papachristodoulou joined our MSc programme at Barts Cancer Institute, Queen Mary University of London, he discovered his passion for cancer research and set out on a career path that led him to launch his own independent lab.
Read more
Scientists discover the ‘roadmap’ that aggressive cancer uses to spread around the body and identify ways to block its escape
14th February 2025
Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body. The findings could help doctors spot which tumours are likely to be aggressive and cause metastatic cancer. They also open new avenues for treating cancer before it spreads.
Read more
Queen Mary’s Barts Cancer Institute co-leads £43.6m initiative to accelerate AI-powered cancer breakthroughs
11th February 2025
Barts Cancer Institute, Queen Mary University of London will co-lead a ground-breaking collaboration, PharosAI, that aims to harness cutting-edge artificial intelligence (AI) and unlock decades of NHS cancer data. The UK government is committing £18.9 million to the project.
Read more
Barts Cancer Institute book celebrates two decades of cancer discovery
4th February 2025
Barts Cancer Institute, Queen Mary Univerity of London, is delighted to announce the publication of a special commemorative book celebrating twenty years of cancer discoveries since the establishment of the institute.
Read more
Professor Louise Jones wins Goudie Medal for excellence in pathology
22nd January 2025
Professor Louise Jones has been awarded the Pathological Society’s prestigious Goudie Medal for her seminal contributions to pathological science and understanding of disease.
Read more
Protein level predicts immunotherapy response in bowel cancer
16th January 2025
Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.
Read more